[1] Schiffman M, Herrero R, Desalle R, Hildesheim A, Wa-cholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 2005, 337(1): 76–84.
[2] Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The ele-vated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the pos-sible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst, 2005, 97(14): 1072–1079.
[3] Castle PE, Solomon D, Schiffman M, Wheeler CM. Hu-man papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst, 2005, 97(14): 1066–1071.
[4] Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG. Human papillomavirus type 16 DNA sequence. Virology, 1985, 145(1): 181–185.
[5] Bontkes HJ, van Duin M, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer PA, Sinnott P, Stern PL. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer, 1998, 78(2): 166–171.
[6] Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in inva-sive cervical carcinoma than the prototype. Cancer Res, 1998, 58(4): 829–833.
[7] Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M. Uni-form distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer, 1999, 82(2): 203–207.
[8] Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tomma- sino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer, 2001, 94(5): 711–716.
[9] Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. Association between human papillomavi-rus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol, 2003, 64(5): 538–542.
[10] Kammer C, Warthorst U, Torrez-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol, 2000, 81(Pt 8): 1975–1981.
[11] Kurvinen K, Yliskoski M, Saarikoski S, Syrjanen K, Syr-janen S. Variants of the long control region of human papillomavirus type 16. Eur J Cancer, 2000, 36(11): 1402–1410.
[12] Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Ro-han T, Franco EL. Molecular variants of human papillomavi-rus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol, 2000, 81(Pt12): 2959–2968.
[13] Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide per-spective. J Virol, 1997, 71(3): 2463–2472.
[14] Pande S, Jain N, Prusty BK, Bhambhani S, Gupta S, Sharma R, Batra S, Das BC. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol, 2008, 46(3): 1060–1066.
[15] Andersson S, Alemi M, Rylander E, Strand A, Larsson B, Sallstrom J, Wilander E. Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions. Br J Cancer, 20 |